Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Cue Biopharma, Inc.NASDAQ: CUE

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses dips below year-ago levels

Q1 FY2026 operating expenses of $11.05M fell 13.1% year over year, behind the +6.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 44.7% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Operating expenses amounted to 196.6% of revenue in FY2025, down 350.3 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -13.1% toward the trailing-twelve-month pace of +6.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.05M-44.7% QoQ
Last fiscal yearDec 2025
$53.99M+6.3% YoY
LTMMar 2026
$52.24M+6.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.1%——
1 year+6.3%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
53.99M USD
Year-over-year change
+6.3%
4-year CAGR
-2.8%

Operating Expenses vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 operating expenses of $52.24M is the 3rd highest of the 7 companies compared; the peer median is $27.15M.
  • Its year-over-year change of +6.3% is the 2nd highest of 7, against a peer median of -31.6%.
  • Operating expenses amounts to 159.6% of revenue for CUE, versus a peer median of 999.7%.
CUE Competitors Peer median
Operating Expenses for CUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$87.08M -41.0%-7.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$59.37M -22.3%+2.5%17821.9%
CUECue Biopharma, Inc.LTM Mar 2026$52.24M +6.3%-0.3%159.6%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$34.01M -44.2%-8.3%—
EQEquillium, Inc.LTM Mar 2026$20.3M -54.6%-32.8%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$18.04M +2.8%-27.4%786.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$14.13M +26.1%-25.3%999.7%
Peer median (excluding CUE) $27.15M-31.6%-16.8%999.7%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.94M1.25M5.49M9.29M27.47M
Cost of Revenue(1.78M)038.1M00
Gross Profit16.72M1.25M(32.61M)9.29M27.47M
Gross Margin111.9%100.0%-593.9%100.0%100.0%
Research & Development41.35M38.58M40.8M36.3M37.74M
Selling, General & Admin17.31M16.17M16.68M14.59M16.24M
Operating Expenses60.43M54.47M19.54M50.79M53.99M
Depreciation & Amortization(1.78M)1.81M3.44M2.35M3.48M
EBITDA(45.44M)(50.49M)(46.05M)(37.53M)(22.27M)
EBITDA Margin-304.1%-4055.5%-838.8%-404.1%-81.1%
Operating Income(43.71M)(53.23M)(52.15M)(41.5M)(26.52M)
Operating Margin-292.6%-4275.1%-949.9%-446.9%-96.6%
Interest Income45.9K928.24K2.66M1.62M807K
Interest Expense0713.82K1.25M796K357K
Other Income / Expenses45.9K215K1.42M826K419K
Income Before Tax(43.67M)(53.01M)(50.73M)(40.67M)(26.1M)
Pre-Tax Margin-292.3%-4257.8%-924.1%-438.0%-95.0%
Income Tax Expense495K000500K
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Net Margin-295.6%-4257.8%-924.1%-438.0%-96.9%
EPS (Basic)(42.30)(44.70)(33.30)(21.60)(8.40)
EPS (Diluted)(42.30)(44.70)(33.30)(21.60)(8.40)
Weighted Avg Shares1.04M1.19M1.53M1.88M3.16M
Weighted Avg Shares (Diluted)1.04M1.19M1.53M1.88M3.16M

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.